Previous 10 | Next 10 |
We have posted our brief quarterly letter. Speed Read: Our underperformance this year reflects irrational prices that have become even less rational, particularly with the view we have on the board of our largest position; Our portfolio has higher FCF growth (+61% in the last 18 mont...
SAN DIEGO , July 3, 2019 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing potential new therapies for cancer, today announced the appointment of Tamar Howson, M.S., MBA, to its board of directors. "I am excited to join MEI wi...
Thinly traded micro cap MEI Pharma (NASDAQ: MEIP ) is up 5% premarket on light volume in response to updated results from a Phase 1b clinical trial evaluating PI3K delta inhibitor ME-401, combined with Roche's ( OTCQX:RHHBY ) Rituxan (rituximab) or BeiGene's (NASDAQ: BGNE ) z...
SAN DIEGO , June 22, 2019 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing potential new therapies for cancer, today announced that updated data presented in an oral presentation at ICML 2019 from a Phase 1b study of investig...
Review of Stock Price Since My Last Article I last wrote about MEI Pharma (MEIP) on July 10th, 2017, with an article titled " MEI Pharma: Double Trouble Or Double Double. " At the time of the article, the stock was trading at $2.76 a share and had already doubled from $1.40 a share early in ...
-- 80% overall response rate in patients with relapsed or refractory follicular lymphoma -- -- Intermittent dosing schedule demonstrates comparable overall response rates with lower rate of delayed Grade 3 adverse events compared to continuous dosing schedule -- SAN DIEGO , June ...
SAN DIEGO , June 1, 2019 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing potential new therapies for cancer, today announced data presented at ASCO 2019 from an investigator-initiated study of investigational ME-344 in combina...
SAN DIEGO , May 31, 2019 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that Daniel P. Gold , Ph.D., president and chief executive officer, will present at the Jefferies 2019 Global ...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 104 weeks of public selections as part of this ongoing live forward-testing. In...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 105 weeks of public selections as part of this ongoing live forward-testing. In...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
16.08%Change Percent:
MEI Pharma Inc. Company Name:
MEIP Stock Symbol:
NASDAQ Market:
MEI Pharma Inc. Website:
Company Commences a Cash Preservation Plan Including a Reduction in Force MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today announced that its Board of Directors has determined unanimously to begin evaluation of the Company’s strategic alternatives, including ...
-- Ongoing Phase 1 Study Evaluating Voruciclib Plus Venetoclax Demonstrates Anti-leukemic Activity, Including Complete Responses, Anticipated Decreases in Mcl-1 and No Overlapping Toxicity in Heavily Pretreated R/R AML Patients -- -- Board of Directors Unanimously Aligned on Prioritizatio...